Table 1. Baseline characteristics in CMV-DNA+ and CMV-DNA− patients (N = 46).
| Characteristics | All (N = 46) | CMV-DNA (+) (n = 12) | CMV-DNA (-) (n = 34) | p value |
|---|---|---|---|---|
| Age (years), median (range) | 44 (16–91) | 66 (23–91) | 39 (16–74) | 0.009 |
| Sex (male) | 26 (56%) | 8 (75%) | 18 (53%) | 0.509 |
| Duration of disease, < 1 year | 18 (39%) | 3 (25%) | 15 (44%) | 0.315 |
| Duration of disease, 1–5 years | 9 (20%) | 3 (25%) | 6 (18%) | 0.678 |
| Duration of disease, > 5 years | 17 (37%) | 6 (50%) | 11 (32%) | 0.314 |
| Duration of disease, Unknown | 2 (4%) | 0 | 2 (6%) | 1.000 |
| Disease activity index, median (range) | 8.5 (2–12) | 9 (5–12) | 8 (2–12) | 0.336 |
| Stool frequency | 2.5 (0–3) | 3 (1–3) | 2 (0–3) | 0.184 |
| Rectal bleeding | 1 (0–3) | 1 (0–3) | 1.5 (0–3) | 0.804 |
| Endoscopic findings | 2.5 (1–3) | 3 (2–3) | 2 (1–3) | 0.032 |
| Physician global assessment | 2 (0–3) | 2 (1–3) | 2 (0–3) | 0.861 |
| Extensive colitis/ Left-sided colitis | 28 (61%)/ 18 (39%) | 9 (75%)/ 3 (25%) | 19 (56%)/ 15 (44%) | 0.315 |
| WBC (103/μl) | 7.7 (3.9–17.1) | 7.5 (3.9–16.0) | 7.7 (3.9–17.1) | 0.980 |
| Hb (g/dl) | 13.0 (7.5–16.3) | 13.4 (9.0–16.3) | 12.9 (7.5–16.0) | 0.754 |
| Platelet (104/μl) | 29.5 (11.0–53.2) | 28.3 (18.0–46.5) | 30.9 (11.0–53.2) | 0.783 |
| Albumin (g/dl) | 3.6 (1.7–4.6) | 3.4 (1.8–3.9) | 3.8 (1.7–4.6) | 0.302 |
| CRP (mg/dl) | 1.1 (0.2–24.1) | 1.5 (0.3–7.4) | 0.8 (0.2–24.1) | 0.744 |
| ESR (mm/h) | 29.0 (2–109) | 32.0 (4.0–85.0) | 29.1 (2–109) | 0.776 |
| CMV antigenemia positive patients a | 5 (19%) | 4 (44%) | 1 (6%) | 0.034 |
| IHC positive patients b | 6 (21%) | 5 (56%) | 1 (51%) | 0.005 |
| 5-ASA use | 37 (80%) | 10 (83%) | 27 (79%) | 1.000 |
| Corticosteroid use | 17 (37%) | 7 (58%) | 10 (29%) | 0.093 |
| Dose of Corticosteroids/4w | 0 (0–1405) | 140 (0–1200) | 0 (0–1405) | 0.046 |
| Azathioprine use | 9 (19%) | 1 (8%) | 7 (21%) | 0.660 |
| Apheresis use | 1 (2%) | 0 | 1 (3%) | 1.000 |
| Tacrolimus use | 2 (4%) | 0 | 1 (3%) | 1.000 |
| Cyclosporine A use | 1 (2%) | 0 | 1 (3%) | 1.000 |
| Infliximab use | 1 (2%) | 0 | 1 (3%) | 1.000 |
aTwenty-six patients underwent CMV antigenemia assay.
bTwenty-nine patient sample were subjected to IHC analysis. We compared nominal variables or continuous variables between both groups using the χ2 test, Fisher’s exact, or Mann-Whitney U tests, as appropriate. Bold value means statistical significance.
Abbreviations: NA, not applicable; WBC, white blood cell; Hb, hemoglobin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IHC, immunohistochemistry; 5-ASA, 5-aminosalicylic acid.